On May 22, 2023, Boehringer Ingelheim announced that the FDA has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm). According to a previous announcement from Boehringer ...
The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial launch on ...
Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...
(Reuters) -Amgen Inc said on Tuesday it launched a biosimilar version of AbbVie Inc's big selling arthritis treatment, the first such competition for Humira in the United States. Amgen said its drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results